Abrégé

The present invention relates to T cells expressing bispecific antibodies for BCMA and CD3 and uses thereof in the treatment of cancer, in particular cancers which overexpress BCMA antigen.

Classes IPC  ?

• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/33 - AnticorpsActivateurs de lymphocytes T
• A61K 40/42 - Antigènes associés au cancer
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

Computer-implemented method of predicting whether a tumour is likely to acquire a gene amplification or deletion are provided, the method comprising obtaining a tumour copy number profile for the tumour; determining, for each of one or more signatures of chromosomal instability, a metric indicative of the presence of the signature in the tumour copy number profile, and determining whether the tumour is likely to acquire a gene amplification or deletion based on the output of a model trained to take as input the values of said metrics and produce as output a score indicative of the likelihood that the tumour will acquire a gene amplification or deletion Methods of predicting treatment response and prognosis, and related systems and products are also described.

Classes IPC  ?

• G16B 20/10 - Ploïdie ou détection du nombre de copies
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G16B 40/20 - Analyse de données supervisée
• C12Q 1/6869 - Méthodes de séquençage
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Methods of analysing targeted genomic sequencing data comprising a plurality of sequencing reads are provided The methods comprise determining an observed read count, from the genomic sequence data, for each of a plurality of genomic bins; and determining a corrected read count for one or more of the plurality of genomic bins, the corrected read count based on the observed read count and one or more estimates of biases in read counts as a function of a variable associated with said respective biases. The biases comprise capture bias and the variable associated with said bias is a capture bias score that is indicative of a difference between an observed read location metric distribution in the bin and an expected read location distribution metric in the bin. Related methods and products are also described.

Classes IPC  ?

• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs

Produits et services

Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic substances for medical use; Diagnostic biomarker reagents for medical purposes; In vitro diagnostic preparations for medical use; Medical diagnostic test kits comprising reagents with biomarkers. Diagnostic apparatus for medical purposes; Tools for medical diagnostics; Diagnostic, examination, and monitoring equipment. Science and technology services; Consultancy in the field of scientific research; Technical research; Advisory services relating to technological research; Research relating to biotechnology; Consultancy in the field of pharmaceutical research; Biological research, clinical research and medical research; Research laboratories; Biochemical research and development; Research on the subject of pharmaceuticals; Bacteriological consultation and research; Clinical research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of vaccines and medicines. Medical diagnostic services; Medical laboratory services for the analysis of samples taken from patients; Medical testing for diagnostic or treatment purposes; Medical testing services relating to the diagnosis and treatment of disease; advice relating to the following fields: Medical diagnostic and treatment tests; Genetic testing for medical purposes; Laboratory analysis services relating to the treatment of animals; Genetic testing of animals for diagnostic or treatment purposes; Consultancy and information services relating to pharmaceutical products; Medical analysis services relating to the treatment of patients.

Produits et services

Diagnostic agents, preparations and substances for medical use; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; In vitro diagnostic preparations for medical use; Medical diagnostic test strips for urine analysis Diagnostic kits consisting primarily of probes, buffers and reagents for use in microbial testing; Medical diagnostic apparatus for detecting cancer Consulting services in the field of the diagnosis and treatment of cancer; Genetic testing for medical purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical diagnostic services; Medical diagnostic testing, monitoring and reporting services; Medical testing services relating to the diagnosis and treatment of disease; Providing information about genetic testing for medical purposes; Urine testing being medical analysis services for diagnostic and treatment purposes provided by medical laboratories

Abrégé

The present invention relates to thiophene derivatives and to the use of these compounds of formula (I) to prevent and/or treat viral diseases. More particularly, the invention relates to the use of these compounds to treat and/or prevent the disease caused by Ebola virus (EBOV) and/or African swine fever (ASF).

Classes IPC  ?

• C07D 333/10 - Thiophène
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 31/12 - Antiviraux

Produits et services

Medical diagnostic services; Medical laboratory services for the analysis of samples taken from patients; Medical analysis services, for diagnostic purposes and For therapeutic purposes; Medical testing services relating to the diagnosis and treatment of disease; Genetic testing for medical purposes; advice relating to the following fields: Medical diagnostic and treatment tests; All the aforesaid for predicting patient response to therapies and treatments relating to cancer.

Produits et services

Diagnostic preparations and materials; Diagnostic preparations for medical purposes; Diagnostic substances for medical use; Diagnostic biomarker reagents for medical purposes; In vitro diagnostic preparations for medical use; Medical diagnostic test kits comprising reagents with biomarkers; All the aforesaid for predicting patient response to therapies and treatments relating to cancer. Diagnostic apparatus and instruments For medical purposes, for use in the following fields: Predicting patient response to therapies and treatments relating to cancer.

Produits et services

Medical diagnostic services; Medical laboratory services for the analysis of samples taken from patients; Medical analysis services, for diagnostic purposes and For therapeutic purposes; Medical testing services relating to the diagnosis and treatment of disease; Genetic testing for medical purposes; advice relating to the following fields: Medical diagnostic and treatment tests; All the aforesaid for predicting patient response to therapies and treatments relating to cancer.

Abrégé

The present invention refers to a pharmaceutical composition comprising Natural Killer (NK) cells transduced with a chimeric antigen receptor (NKG2D CAR-NK or BCMA CAR-NK cells), and at least one NKG2A blocking agent and its use as a medicament. The present invention also refers to a pharmaceutical composition comprising CAR-NK cells for use in the treatment of several types of cancer, wherein said composition is administered before, simultaneously with, or after administering at least one NKG2A blocking agent.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/725 - Récepteurs de lymphocytes-T
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

HVHVctctctctt 2; (H) determining (i) the minimum variant read frequency, minVRF, of said genetic marker, (ii) the limit ofdetection, D-limit, of said genetic marker (iii) the average mutation noise, avMut and (iv) the average position noise, avPos; (I) determining the experimental sensitivity, ES, from the greater of the minVRF, D-limit, avMut and avPos or from the greater of minVRF and D-limit; (J) determining the presence or absence of minimal residual disease in said subject by comparing the value of the level of minimal residual disease with the value of ES, the values of minVRF, D-limit, avMut and avPos, or the values of minVRF and D-limit; wherein when said level of minimal residual disease is equal to or greater than said ES, minVRF, D-limit, avMut or avPos values, minimal residual disease is present in said subject.

Classes IPC  ?

• C12Q 1/6858 - Amplification spécifique d’allèles
• C12Q 1/6851 - Amplification quantitative
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
• G16B 25/20 - Réaction en chaîne par polyméraseConception d’amorces ou de sondesOptimisation de la sonde
• G16B 30/10 - Alignement de séquenceRecherche d’homologie

Abrégé

The invention relates to a novel biomarker for the diagnosis, prognosis and monitoring of early-onset colorectal cancer, the gene NOMO-1 or any of the expression products thereof. As such, the invention also relates to an in vitro method of diagnosis, prognosis and monitoring of early-onset colorectal cancer, in which said biomarker must be quantified in a biological sample containing tumour cells.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a continuous pasteuriser for human milk, which enables pathogenic microorganisms in the milk to be eliminated and the nutritional and immunological quality thereof to be improved. The pasteuriser comprises: an inlet tank (1) and an outlet tank (8) with agitation systems (2, 9) in each tank; a peristaltic pump (4); a heating circuit (5) in which pasteurisation takes place at a temperature between 72 and 75°C for a period of 10 to 20 seconds at a flow rate of 10 l/h; and a cooling circuit (6) integrated with a mechanical system (7) for producing coldness, allowing the milk to be released at a temperature between 2 and 4°C for the subsequent packaging thereof in optimal hygienic and sanitary conditions. All of the components and processes are regulated by means of a control unit (12).

Classes IPC  ?

• A23C 3/03 - Conservation du lait ou de préparations à base de lait par chauffage les produits étant en vrac et non emballés

Abrégé

The invention relates to the use of an isolated peptide, an antibody or a fusion protein that can bind to NPCT, and the compositions and pharmaceutical forms comprising same, in the development of a medicament for the treatment and/or prevention of diseases related to the increase in beta-amyloids and/or tau hyperphosphorylation and/or neurotoxicity induced by domoic acid.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Produits et services

Scientific research and laboratory apparatus, educational apparatus and simulators. Medical and veterinary apparatus and instruments; Diagnostic, examination, and monitoring equipment; Apparatus for the treatment of cancer. Science and technology services; Scientific investigations for medical purposes; Scientific research for medical purposes in the area of cancerous diseases; Scientific research and development. Human healthcare services; Professional consultancy relating to health; Consulting services relating to health care; Advisory services relating to medical instruments; Advisory services relating to medical services.

Abrégé

The invention relates to a method for transmission infrared spectroscopy for determining the degree of global cognitive deterioration associated with Alzheimer's disease, on the basis of analysis of the 3100-1300 cm-1 region of the infrared spectrum of a previously obtained and fractionated blood sample. The fractionated blood sample to be analyzed is preferably a leucocyte fraction. Likewise, the invention relates to the use of said method to obtain an indication of the status of the Alzheimer's disease and/or an indication of the degree of cognitive deterioration associated with said disease.

Classes IPC  ?

• G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge

Produits et services

Printed publications, catalogues, magazines, printed matter, leaflets. Teaching and providing of training, arranging of courses, congresses and conferences for cultural and training purposes. Scientific and technological services and biomedical research, basic and clinical research.